Who is eligible for clinical trial NCT05775159?

Participants must meet protocol criteria for Hepatocellular Carcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05775159 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-21

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (NCT05775159)

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Who can join: Review the eligibility criteria below.

Location: Research Site — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (46 Sites)

Showing the first 25 of 46 sites.

Research Site — Birmingham, Alabama
Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — Kansas City, Kansas
Research Site — New York, New York
Research Site — Beijing,
Research Site — Beijing,
Research Site — Beijing,
Research Site — Chengdu,
Research Site — Chengdu,
Research Site — Chongqing,
Research Site — Fuzhou,
Research Site — Guangzhou,
Research Site — Guangzhou,
Research Site — Harbin,
Research Site — Nanning,
Research Site — Shanghai,
Research Site — Hong Kong,
Research Site — Shatin,
Research Site — Florence,
Research Site — Milan,
Research Site — Naples,
Research Site — Rozzano,
Research Site — Chūōku,
Research Site — Kashiwa,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hepatocellular Carcinoma

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona

Explore by condition: All Hepatocellular Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗